AbCellera Biologics (ABCL US)

Analysis

Health Care • Canada

AbCellera Biologics Inc. operates as a pharmaceutical company. The Company discovers and develops next generation therapeutic antibodies through combination of technologies including proprietary immunizations, microfluidics, high-throughput imaging, genomics, computation, and laboratory automation. AbCellera Biologics serves customers in Canada.

Refresh

Exchange Announcement • 14 Aug 2026 04:33

Current Report (Form 8-K | Period ending 2026-08-12)

Exchange Announcement • 14 Aug 2026 04:31

424B5 | Prospectus

Exchange Announcement • 12 Aug 2026 04:59

424B5 | Prospectus

Exchange Announcement • 10 Aug 2026 19:49

Current Report (Form 8-K | Period ending 2026-08-10)

Exchange Announcement • 08 Aug 2026 04:43

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Current Report (Form 8-K | Period ending 2026-08-12)

424B5 | Prospectus

424B5 | Prospectus

Current Report (Form 8-K | Period ending 2026-08-10)

Current Report (Form 8-K | Period ending 2026-08-07)